Spondyloarthritis

Researchers report that patients with psoriatic arthritis face significantly higher risk of cardiovascular and cerebrovascular morbidity compared with the general population.

When a patient is dying, it can be difficult to know what to say to them. Here are a few tips and approaches that I have gathered from experts that I hope will help you get through those hard conversations while continuing to provide the best possible care to your patient.

Analysis of trial data found that etanercept monotherapy treats psoriatic arthritis as effectively as the combination of etanercept and methotrexate.

Researchers report that a lipid mediator known as resolvin D1 demonstrated anti-arthritis properties in mice models.

Compounds in the body may help reduce inflammation and prevent damage to healthy tissues for arthritis patients and patients with other inflammatory diseases.

Researchers warn that non-steroidal anti-inflammatory drugs (NSAIDs) are more dangerous than previously thought, and should be prescribed with great care among patients with heart disease.

Researchers have concluded that there is a small but significant genetic component to the observed connection between high body mass index (BMI) and psoriasis.

An analysis of health records indicates that smoking is not associated with joint damage in psoriatic arthritis patients.

Researchers explored how people aged 16 to 25 years old with inflammatory arthritis evaluate the risks and benefits of treatment. They especially wanted to focus on the patients’ assessments of biologic therapies.

An analysis of records from the Toronto Psoriatic Arthritis Cohort concluded that baseline characteristics can help predict which patients will and will not develop erosions.

Top-line results from a phase 3 trial indicate that twice-daily tofacitinib 5 mg and 10 mg are both superior to placebo in the treatment of psoriatic arthritis.

Several symptoms, including nail pitting and uveitis, may indicate an increased risk for developing psoriatic arthritis.

The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.

Analysis of 3 apremilast trials finds that the medication increases workplace productivity and reduces workplace limitations for at least a year in patients who began trials with inadequately controlled psoriatic arthritis.

A new analysis of treatment costs and trial outcomes concludes that immediate use of tumor necrosis factor inhibitors (TNFis) is a cost-effective strategy for managing psoriatic arthritis patients with both skin and joint involvement but not for managing those patients with joint disease alone.

A new trial of magnetic resonance imaging finds that analyzing scans for subclinical signs of inflammatory joint disease can help predict which psoriasis patients will go on to develop psoriatic arthritis.

A 96-week-long trial of etanercept (Enbrel) indicates durable therapeutic benefits and no serious adverse events in pediatric patients with psoriatic arthritis and other types of juvenile idiopathic arthritis.